Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SAR405838 + pimasertib in advanced cancer
NL-OMON40404Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAR-405838 and pimasertib in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Sanofi. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose and Tumor response and duration in RP2D expansion. Started Nov 2013; status: active, not recruiting.
02
Drugs
SAR-405838pimasertib
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON40404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40404.